Abstract
Background As part of on-going efforts to contain the COVID-19 pandemic, understanding the role of asymptomatic patients in the transmission system is essential to infection control. However, optimal approach to risk assessment and management of asymptomatic cases remains unclear.
Methods This study involved a SEINRHD epidemic propagation model, constructed based on epidemiological characteristics of COVID-19 in China, accounting for the heterogeneity of social network. We assessed epidemic control measures for asymptomatic cases on three dimensions. Impact of asymptomatic cases on epidemic propagation was examined based on the effective reproduction number, abnormally high transmission events, and type and structure of transmission.
Results Management of asymptomatic cases can help flatten the infection curve. Tracking 75% of asymptomatic cases corresponds to an overall reduction in new cases by 34.3% (compared to tracking no asymptomatic cases). Regardless of population-wide measures, family transmission is higher than other types of transmission, accounting for an estimated 50% of all cases.
Conclusions Asymptomatic case tracking has significant effect on epidemic progression. When timely and strong measures are taken for symptomatic cases, the overall epidemic is not sensitive to the implementation time of the measures for asymptomatic cases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Natural Science Foundation of China (Nos.72042018,91546112, 71621002) and Beijing Municipal Natural Science Foundation (No. L192012).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research is a simulation experiment, no IRB approval is required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the supplemental material and it can be open accessed.
1Abbreviations
- COVID-19
- Coronavirus Disease of 2019.
